{
    "clinical_study": {
        "@rank": "4951", 
        "arm_group": {
            "arm_group_label": "Continuous Glucose Monitoring System", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the system performance of the GlySure Continuous\n      Glucose Monitoring (CGM) system in patients admitted to the Surgical Intensive Care Unit."
        }, 
        "brief_title": "A Comparative Study to Evaluate the Accuracy and Safety of the GlySure Continuous Intravascular Glucose Monitoring System Versus Intermittent Blood Glucose Monitoring", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Continuous Glucose Measurement", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patient or legal representative MUST be willing to sign an informed consent document\n\n          2. Male and female aged 18 years and above\n\n          3. Require Central Venous Catheter (CVC) into the right internal Jugular vein as part of\n             disease management and treatment\n\n          4. Expected to remain in the Surgical Intensive Care Unit (SICU) for at least 30 hours\n             and up to 7 days-\n\n        Exclusion Criteria:\n\n          1. Patient or legal representative unable to provide written informed consent\n\n          2. Patient who is pregnant\n\n          3. Patient who is currently being administered Mannitol\n\n          4. Patient with history of Pulmonary Embolism (PE)\n\n          5. Patient with history of thrombosis\n\n          6. Patient with known hyper-coagulation\n\n          7. Patient with known history of heparin hypersensitivity\n\n          8. Patient with history of heparin induced thrombocytopenia\n\n          9. Participation in a clinical study involving an unlicensed pharmaceutical product\n             and/or device within the 3 months prior to enrolment in this study\n\n         10. Patient with known hypersensitivity/allergy to adhesive I.V. dressings such as 3M\n             Tegaderm film\n\n         11. Patient likely to require an MRI scan during their stay in the SICU\n\n         12. Patients likely to require treatment with Mannitol during time in the SICU"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "38", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01942902", 
            "org_study_id": "2013.01.CE"
        }, 
        "intervention": {
            "arm_group_label": "Continuous Glucose Monitoring System", 
            "intervention_name": "Continuous Glucose Monitoring System", 
            "intervention_type": "Device", 
            "other_name": "Glysure"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 5, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Banjara Hills", 
                        "country": "India", 
                        "state": "Hyderabad", 
                        "zip": "500034"
                    }, 
                    "name": "Star Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nampally", 
                        "country": "India", 
                        "state": "Hyderabad", 
                        "zip": "500001"
                    }, 
                    "name": "Care Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "India"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Comparative Study to Evaluate the Accuracy and Safety of the GlySure Continuous Intravascular Glucose Monitoring System Versus Intermittent Blood Glucose Monitoring Using the Yellow Springs Blood Glucose Analyser for Conformit\u00e9 Europ\u00e9enne (CE) Marking Purposes in a Total of Thirty Patients Admitted to The Surgical Intensive Care Unit (SICU)", 
        "overall_official": {
            "affiliation": "Care Hospital", 
            "last_name": "Krishna Prasad, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "India: Care Foundation Ethics Committee", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "The study is designed to evaluate the comparative accuracy between measured blood glucose results obtained from the GlySure Continuous Glucose Monitoring System (CGM) and the YSI, and to determine if any condition or treatment affects the sensor's measured values.", 
                "measure": "Accuracy of the CGM system as compared with the Yellow Springs Instrument (YSI) blood sample analysis results", 
                "safety_issue": "No", 
                "time_frame": "For at least 30 hours and up to 7 days"
            }, 
            {
                "measure": "Number of participants experiencing Serious Adverse Events (SAEs) causally related to the devices", 
                "safety_issue": "Yes", 
                "time_frame": "For at least 30 hours and up to 7 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01942902"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "GlySure", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlySure", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}